Europe Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

Europe Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  151 | No. Tables:  106 | No. Figures:  71

Market Definition

Europe Professional Acne Medication Market was valued at USD 828.32 million in 2023 and is predicted to reach USD 1521.60 million by 2030, with a CAGR of 9.1% from 2024 to 2030. The professional acne medicine market refers to dermatologist-prescribed specialist skincare formulations for focused and effective acne therapy, treating both inflammatory and non-inflammatory lesions while reducing scarring. These formulations provide benefits such as powerful and customized chemicals, frequently outperforming over-the-counter alternatives.

Professional acne treatments, which are widely used in dermatological services, cater to those who have severe or persistent acne problems, assuring a better degree of efficacy and control. As the demand for advanced skincare grows, this industry will remain critical in delivering tailored and medically guided ways to cleaner, healthier skin.

Introduction of Innovative Dermatological Procedures Fuels Market Growth

Advancements in treatment options are a key driver of growth in the professional acne medication market in Europe. Surge in innovative dermatological procedures, prescription medications, and specialized skincare products, catering to the specific needs of individuals with acne. These advancements have transformed the landscape of acne treatment by offering more effective and personalized solutions. Specialized skincare products, such as medicated creams and serums, are increasingly formulated with advanced ingredients, ensuring improved outcomes and a better overall experience for those seeking professional acne treatment. These innovations not only promise better results but also drive consumer confidence, contributing to market growth in Europe.

 

Prevalence of Advanced Healthcare Infrastructure Drives the Growth Market

The growth of the professional acne medication market in Europe is significantly bolstered by the region's advanced healthcare infrastructure. With well-established medical facilities and dermatological clinics, individuals have easy access to cutting-edge treatments for acne-related concerns. The presence of state-of-the-art technologies and specialized healthcare professionals enhances the quality and efficacy of professional acne medications. Europe's advanced healthcare infrastructure not only facilitates the availability of a wide range of treatment options but also ensures that individuals can receive personalized and specialized care, driving the overall demand for professional acne medications in the region.

 

High Healthcare Costs and Limited Insurance Coverage Hinders the Market Growth

High healthcare costs and limited insurance coverage in certain European countries present a significant restraint on the growth of the professional acne medication market. Acne treatment often involves a range of procedures, prescription medications, and consultations with dermatologists, all of which can accumulate substantial costs. People opt for self-care or over-the-counter solutions to manage their acne rather than investing in professional treatments, thereby impeding the growth of the professional acne medication market.

Technological Advancements Presents Opportunity for Growth of the Market

Technological Advancements hold a promising future for the growth of the professional acne medication market in Europe. Continual progress in medical devices, particularly in areas like laser technology and microneedling, is poised to revolutionize the landscape of acne treatments. These innovations offer more effective and less invasive options, contributing to improved patient outcomes and overall satisfaction. As technology evolves, these developments will attract a broader spectrum of patients, propelling the growth of the professional acne medication market by meeting the demand for more advanced and patient-friendly solutions.

Germany Holds the Dominant Market Share in the European Market

Germany's excellent healthcare standards and strong skincare focus are key factors driving future growth opportunities in the professional acne medication market. The nation's world-class healthcare infrastructure and cultural emphasis on dermatological health stimulate demand for professional acne treatments. Patients in Germany have high confidence in the quality and safety of professional skincare, leading to increased investment in advanced treatments, prescription medications, and specialized skincare products.

Additionally, Germany's growth prospects in the professional acne medication market are notably bolstered by its affluent population. The nation's economic prosperity ensures that a substantial portion of its residents possess the financial means to access professional acne treatments. The affluence of the population is enhancing the market's potential for growth as more individuals are investing in comprehensive and advanced acne treatments, contributing to an increasing the demand for professional acne medication market in Germany.

The Netherlands is Expected to Show Steady Growth in the Europe Market

The robust presence of dermatology expertise is a pivotal factor in the Netherlands' expected steady growth in the professional acne medication market within the broader European region. The country boasts a well-established network of highly skilled dermatologists and skin care professionals who specialize in providing advanced and tailored acne treatments. This availability of specialized knowledge and skills positions the Netherlands as a prominent contributor to the growing European professional acne medication market, offering patients a wealth of expert options for their skincare needs.

Moreover, the Netherlands's alignment with health and wellness trends is driving market growth. Dutch consumers are notably health-conscious, actively keeping up with the latest wellness trends. This includes a heightened focus on professional skincare treatments for effective acne management. The Dutch population's awareness of the connection between skincare and overall well-being positions the Netherlands as a thriving hub within the broader European market for professional acne medication.

 

Competitive Landscape

The Europe professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

Europe Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

By Geography

  • Europe

    • UK

    • Germany

    • France

    • Spain

    • Italy

    • Netherlands

    • Rest of Europe

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 828.32 Million

Revenue Forecast in 2030

USD 1521.60 Million

Growth Rate

CAGR of 9.1% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Introduction of Innovative Dermatological Procedures.

Prevalence of Advanced Healthcare Infrastructure

Countries Covered

6

Key Market Players

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      EUROPE PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6      EUROPE PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE

                         6.2.1      INFLAMMATORY ACNE MARKET, BY COUNTRY

           6.3      NON-INFLAMMATORY ACNE

                         6.3.1      NON-INFLAMMATORY ACNE MARKET, BY COUNTRY

7      EUROPE PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS

                         7.2.1      TOPICAL MEDICATIONS MARKET, BY COUNTRY

           7.3      ORAL MEDICATIONS

                         7.3.1      ORAL MEDICATIONS MARKET, BY COUNTRY

8      EUROPE PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS

                         8.2.1      RETINOIDS MARKET, BY COUNTRY

           8.3      ANTIBIOTICS

                         8.3.1      ANTIBIOTICS MARKET, BY COUNTRY

           8.4      SALICYLIC ACID

                         8.4.1      SALICYLIC ACID MARKET, BY COUNTRY

           8.5      BENZOYL PEROXIDE

                         8.5.1      BENZOYL PEROXIDE MARKET, BY COUNTRY

           8.6      OTHERS

                         8.6.1      OTHERS MARKET, BY COUNTRY

9      EUROPE PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA

                         9.2.1      MED SPA MARKET, BY COUNTRY

           9.3      AESTHETICIAN

                         9.3.1      AESTHETICIAN MARKET, BY COUNTRY

           9.4      DERMATOLOGIST

                         9.4.1      DERMATOLOGIST MARKET, BY COUNTRY

           9.5      OTHER PROFESSIONAL CHANNELS

                         9.5.1      OTHER PROFESSIONAL CHANNELS MARKET, BY COUNTRY

10   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY COUNTRY

           10.1   OVERVIEW

           10.2   GERMANY

                         10.2.1   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.2.2   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.2.3   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.2.4   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.3   FRANCE

                         10.3.1   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.3.2   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.3.3   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.3.4   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.4   ITALY

                         10.4.1   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.4.2   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.4.3   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.4.4   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.5   SPAIN

                         10.5.1   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.5.2   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.5.3   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.5.4   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.6   UNITED KINGDOM

                         10.6.1   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.6.2   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.6.3   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.6.4   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.7   NETHERLANDS

                         10.7.1   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.7.2   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.7.3   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.7.4   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.8   REST OF EUROPE

                         10.8.1   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.8.2   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.8.3   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.8.4   EUROPE PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11   COMPANY PROFILES

           11.1   ALMIRALL S.A.

                         11.1.1   COMPANY OVERVIEW

                         11.1.2   COMPANY SNAPSHOT

                         11.1.3   OPERATING BUSINESS SEGMENTS

                         11.1.4   PRODUCT PORTFOLIO

                         11.1.5   BUSINESS PERFORMANCE

                         11.1.6   BUSINESS SEGMENTS

                         11.1.7   GEOGRAPHIC SEGMENTS

                         11.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.1.9   PRIMARY MARKET COMPETITORS

           11.2   BAUSCH HEALTH COMPANIES, INC.

                         11.2.1   COMPANY OVERVIEW

                         11.2.2   COMPANY SNAPSHOT

                         11.2.3   OPERATING BUSINESS SEGMENTS

                         11.2.4   PRODUCT PORTFOLIO

                         11.2.5   BUSINESS PERFORMANCE

                         11.2.6   BUSINESS SEGMENTS

                         11.2.7   GEOGRAPHIC SEGMENTS

                         11.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.2.9   PRIMARY MARKET COMPETITORS

           11.3   GLAXOSMITHKLINE PLC (GSK)

                         11.3.1   COMPANY OVERVIEW

                         11.3.2   COMPANY SNAPSHOT

                         11.3.3   OPERATING BUSINESS SEGMENTS

                         11.3.4   PRODUCT PORTFOLIO

                         11.3.5   BUSINESS PERFORMANCE

                         11.3.6   BUSINESS SEGMENTS

                         11.3.7   GEOGRAPHIC SEGMENTS

                         11.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.3.9   PRIMARY MARKET COMPETITORS

           11.4   GALDERMA S.A.

                         11.4.1   COMPANY OVERVIEW

                         11.4.2   COMPANY SNAPSHOT

                         11.4.3   OPERATING BUSINESS SEGMENTS

                         11.4.4   PRODUCT PORTFOLIO

                         11.4.5   BUSINESS PERFORMANCE

                         11.4.6   BUSINESS SEGMENTS

                         11.4.7   GEOGRAPHIC SEGMENTS

                         11.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.4.9   PRIMARY MARKET COMPETITORS

           11.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         11.5.1   COMPANY OVERVIEW

                         11.5.2   COMPANY SNAPSHOT

                         11.5.3   OPERATING BUSINESS SEGMENTS

                         11.5.4   PRODUCT PORTFOLIO

                         11.5.5   BUSINESS PERFORMANCE

                         11.5.6   BUSINESS SEGMENTS

                         11.5.7   GEOGRAPHIC SEGMENTS

                         11.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.5.9   PRIMARY MARKET COMPETITORS

           11.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         11.6.1   COMPANY OVERVIEW

                         11.6.2   COMPANY SNAPSHOT

                         11.6.3   OPERATING BUSINESS SEGMENTS

                         11.6.4   PRODUCT PORTFOLIO

                         11.6.5   BUSINESS PERFORMANCE

                         11.6.6   BUSINESS SEGMENTS

                         11.6.7   GEOGRAPHIC SEGMENTS

                         11.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.6.9   PRIMARY MARKET COMPETITORS

           11.7   JOHNSON AND JOHNSON

                         11.7.1   COMPANY OVERVIEW

                         11.7.2   COMPANY SNAPSHOT

                         11.7.3   OPERATING BUSINESS SEGMENTS

                         11.7.4   PRODUCT PORTFOLIO

                         11.7.5   BUSINESS PERFORMANCE

                         11.7.6   BUSINESS SEGMENTS

                         11.7.7   GEOGRAPHIC SEGMENTS

                         11.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.7.9   PRIMARY MARKET COMPETITORS

           11.8   ELI LILLY AND COMPANY

                         11.8.1   COMPANY OVERVIEW

                         11.8.2   COMPANY SNAPSHOT

                         11.8.3   OPERATING BUSINESS SEGMENTS

                         11.8.4   PRODUCT PORTFOLIO

                         11.8.5   BUSINESS PERFORMANCE

                         11.8.6   BUSINESS SEGMENTS

                         11.8.7   GEOGRAPHIC SEGMENTS

                         11.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.8.9   PRIMARY MARKET COMPETITORS

           11.9   MYLAN N.V.

                         11.9.1   COMPANY OVERVIEW

                         11.9.2   COMPANY SNAPSHOT

                         11.9.3   OPERATING BUSINESS SEGMENTS

                         11.9.4   PRODUCT PORTFOLIO

                         11.9.5   BUSINESS PERFORMANCE

                         11.9.6   BUSINESS SEGMENTS

                         11.9.7   GEOGRAPHIC SEGMENTS

                         11.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.9.9   PRIMARY MARKET COMPETITORS

           11.10   DAIICHI SANKYO COMPANY, LTD

                         11.10.1   COMPANY OVERVIEW

                         11.10.2   COMPANY SNAPSHOT

                         11.10.3   OPERATING BUSINESS SEGMENTS

                         11.10.4   PRODUCT PORTFOLIO

                         11.10.5   BUSINESS PERFORMANCE

                         11.10.6   BUSINESS SEGMENTS

                         11.10.7   GEOGRAPHIC SEGMENTS

                         11.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 4. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 7. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 13. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 18. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 19. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 20. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 21. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 22. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 23. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 24. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 25. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 26. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 27. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 28. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 29. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 30. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 31. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 32. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 33. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 34. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 35. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 36. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 37. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 38. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 39. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 40. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 41. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 42. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 43. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 44. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 45. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 46. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 47. ALMIRALL S.A.: COMPANY SNAPSHOT

TABLE 48. ALMIRALL S.A.: OPERATING BUSINESS SEGMENTS

TABLE 49. ALMIRALL S.A.: PRODUCT PORTFOLIO

TABLE 50. ALMIRALL S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 51. ALMIRALL S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 52. ALMIRALL S.A.: KEY STRATERGY

TABLE 53. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 54. BAUSCH HEALTH COMPANIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 55. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 56. BAUSCH HEALTH COMPANIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 57. BAUSCH HEALTH COMPANIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 58. BAUSCH HEALTH COMPANIES, INC.: KEY STRATERGY

TABLE 59. GLAXOSMITHKLINE PLC (GSK): COMPANY SNAPSHOT

TABLE 60. GLAXOSMITHKLINE PLC (GSK): OPERATING BUSINESS SEGMENTS

TABLE 61. GLAXOSMITHKLINE PLC (GSK): PRODUCT PORTFOLIO

TABLE 62. GLAXOSMITHKLINE PLC (GSK): SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 63. GLAXOSMITHKLINE PLC (GSK): SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 64. GLAXOSMITHKLINE PLC (GSK): KEY STRATERGY

TABLE 65. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 66. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 67. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 68. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 69. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 70. GALDERMA S.A.: KEY STRATERGY

TABLE 71. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 72. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 73. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 74. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 75. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 76. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGY

TABLE 77. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 78. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS

TABLE 79. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 80. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 81. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 82. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

TABLE 83. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 84. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 85. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 86. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 87. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 88. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 89. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 90. ELI LILLY AND COMPANY: OPERATING BUSINESS SEGMENTS

TABLE 91. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 92. ELI LILLY AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 93. ELI LILLY AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 94. ELI LILLY AND COMPANY: KEY STRATERGY

TABLE 95. MYLAN N.V.: COMPANY SNAPSHOT

TABLE 96. MYLAN N.V.: OPERATING BUSINESS SEGMENTS

TABLE 97. MYLAN N.V.: PRODUCT PORTFOLIO

TABLE 98. MYLAN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 99. MYLAN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 100. MYLAN N.V.: KEY STRATERGY

TABLE 101. DAIICHI SANKYO COMPANY, LTD: COMPANY SNAPSHOT

TABLE 102. DAIICHI SANKYO COMPANY, LTD: OPERATING BUSINESS SEGMENTS

TABLE 103. DAIICHI SANKYO COMPANY, LTD: PRODUCT PORTFOLIO

TABLE 104. DAIICHI SANKYO COMPANY, LTD: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 105. DAIICHI SANKYO COMPANY, LTD: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 106. DAIICHI SANKYO COMPANY, LTD: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 9. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 12. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 18. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 23. EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY REGION 2023-2030, (MILLION USD)

FIGURE 24. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 25. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 26. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 27. GERMANY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 28. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 29. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 30. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 31. FRANCE EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 32. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 33. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 34. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 35. ITALY EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 36. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 37. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 38. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 39. SPAIN EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 40. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 41. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 42. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 43. UNITED KINGDOM EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 44. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 45. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 46. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 47. NETHERLANDS EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 48. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 49. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 50. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 51. REST OF EUROPE PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 52. ALMIRALL S.A.: NET SALES, (2021-2023)

FIGURE 53. ALMIRALL S.A.: PRIMARY MARKET COMPETITORS

FIGURE 54. BAUSCH HEALTH COMPANIES, INC.: NET SALES, (2021-2023)

FIGURE 55. BAUSCH HEALTH COMPANIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 56. GLAXOSMITHKLINE PLC (GSK): NET SALES, (2021-2023)

FIGURE 57. GLAXOSMITHKLINE PLC (GSK): PRIMARY MARKET COMPETITORS

FIGURE 58. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 59. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 60. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, (2021-2023)

FIGURE 61. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2021-2023)

FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS

FIGURE 64. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 65. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 66. ELI LILLY AND COMPANY: NET SALES, (2021-2023)

FIGURE 67. ELI LILLY AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 68. MYLAN N.V.: NET SALES, (2021-2023)

FIGURE 69. MYLAN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 70. DAIICHI SANKYO COMPANY, LTD: NET SALES, (2021-2023)

FIGURE 71. DAIICHI SANKYO COMPANY, LTD: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Almirall SA

  • Bausch Health Companies, Inc.

  • GlaxoSmithKline Plc (GSK)

  • Galderma SA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Johnson & Johnson

  • STRATA Skin Sciences, Inc.

  • Mayne Pharma Group Limited

  • Pfizer, Inc.


Frequently Asked Questions
What will be the worth of the Europe professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the Europe professional acne medication market business is expected to hit at USD 1521.60 million by 2030.

What are the leading companies in the Europe professional acne medication market?

The Europe professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc, Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company, Ltd and others.

What are the market segmentations and scope of the study for the Europe professional acne medication industry?

The Europe professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in Europe?

The growth of the professional acne medication market in Europe is primarily driven by rapid advancements in treatment options and acquisition strategies by market players.

What is restraining the growth of the Europe professional acne medication market?

The high healthcare costs and limited insurance coverage in certain European countries present a substantial restraint on the market's growth in Europe.